Cargando…

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy

Detalles Bibliográficos
Autores principales:	Esker, S, Albano, J, Tilson, H, Uy, J, Arikan, D, Krantz, K, Jiménez-Expósito, MJ, Seekins, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112888/ http://dx.doi.org/10.1186/1758-2652-13-S4-P113

Ejemplares similares

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients
por: Jansen, K, et al.
Publicado: (2010)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis
por: Zolopa, A, et al.
Publicado: (2010)

Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome
por: Baudry, T, et al.
Publicado: (2010)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
por: Bonora, S, et al.
Publicado: (2010)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
por: Siccardi, M, et al.
Publicado: (2010)

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
por: Billaud, E, et al.
Publicado: (2010)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry
por: Vannappagari, V, et al.
Publicado: (2015)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study
por: Meijide, Héctor, et al.
Publicado: (2010)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)
por: Izzo, I, et al.
Publicado: (2010)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Effectiveness of psychosocial intervention for teenage pregnancy on low birth weight and preterm birth outcomes: a systematic review and meta-analysis
por: Sukhato, Kanokporn, et al.
Publicado: (2014)

Mesenchymal stem cell repair capabilities are defective in rheumatoid arthritis in relation with in vivo exposure to inflammation
por: Jones, E, et al.
Publicado: (2007)

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
por: Kuemmerle-Deschner, J, et al.
Publicado: (2011)

Predicting pregnancy rate and live birth rate in the IVF clinic by analysing patient profiles
por: Wang, Shangshang, et al.
Publicado: (2015)

Immunity in Nigerian women and the effects of pregnancy and infectious disease exposure on fetal immunity
por: Cairo, Cristiana, et al.
Publicado: (2006)

Birth defects and associated antenatal care factors related with 1st trimester of pregnancy
por: Zile-Velika, I, et al.
Publicado: (2022)

Clinical significance of hyperbilirubinemia in the CASTLE study
por: Uy, J, et al.
Publicado: (2010)

Pre-pregnancy exposure to arsenic in diet and non-cardiac birth defects
por: Suhl, Jonathan, et al.
Publicado: (2023)

Risk factors for juvenile idiopathic arthritis: exposure to tobacco and environmental factors during and before pregnancy
por: França, Camila MP, et al.
Publicado: (2014)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Birth defects: etiology to prevention
por: Godbole, Koumudi
Publicado: (2014)

Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r)-Containing Regimens in Treatment-Experienced Patients with HIV
por: Svedhem-Johansson, Veronica, et al.
Publicado: (2013)

Evaluation of the factors affecting the prognosis of patients with solid tumors and hematologic malignancies in the intensive care unit
por: Savran, Y, et al.
Publicado: (2015)

Maternal cow’s milk consumption during pregnancy is inversely associated with the risk of cow’s milk allergy (CMA) in the offspring in a prospective birth cohort study
por: Tuokkola, Jetta, et al.
Publicado: (2011)

Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia
por: Dorresteijn, Mirrin J., et al.
Publicado: (2023)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events
por: Coyle, P K, et al.
Publicado: (2014)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k9nupl4sc0ovgsci8l9o5s8mnn